Source-grounded facts extracted from ROCKWELL MEDICAL, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ROCKWELL MEDICAL, INC. shareholders approved To approve and adopt an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s common stock. at the 2026-06-12 meeting.
“Proposal Four: To approve and adopt an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s common stock. For Against Abstain 16,993,038 6,597,036 223,632”
ROCKWELL MEDICAL, INC. shareholders approved To ratify the selection of EisnerAmper LLP as the Company’s independent registered public accounting firm for 2026. at the 2026-06-12 meeting.
“Proposal Three: To ratify the selection of EisnerAmper LLP as the Company’s independent registered public accounting firm for 2026. For Against Abstain 22,996,530 698,744 118,432”
ROCKWELL MEDICAL, INC. shareholders approved To approve, on an advisory basis, the compensation of the Company's named executive officers. at the 2026-06-12 meeting.
“Proposal Two: To approve, on an advisory basis, the compensation of the Company's named executive officers. For Against Abstain Broker Non-Votes 8,232,918 2,682,354 96,595 12,801,839”
ROCKWELL MEDICAL, INC. shareholders approved To elect the two Class II directors to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified. at the 2026-06-12 meeting.
“Proposal One: To elect the two Class II directors to serve for a three-year term expiring at the 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified. For Against Abstain Broker Non-Votes Joseph Dawson 9,812,114 869,022 330,731 12,801,839 Joan Lau, Ph.D. 9,890,379 729,615 391,873 12,801,839”
ROCKWELL MEDICAL, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“May 8, 2026, Rockwell Medical, Inc. (the “Company”) received written notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price require”
ROCKWELL MEDICAL, INC. reported fiscal year 2026 results: revenue $70.0M to $75.0M.
“Rockwell Medical updates its 2026 annual guidance as follows: 2026 Annual Guidance Net Sales $70.0M to $75.0M Gross Margin 18% to 22% Adjusted EBITDA $1.0M to $2.0M Operating Cash Flow Positive”
ROCKWELL MEDICAL, INC. reported the three months ended March 31, 2026 results: revenue $17.3 million, net income $1.6 million, EPS $(0.04).
“reference in such a filing. --- EX-99.1 (EX-99.1) --- Rockwell Medical Announces First Quarter 2026 Results and Additional 2026 Guidance with Focus on Profitability • Reports $17.3 million in net sales, $2.9 million in gross profit, and 17% gross margin in the first quarter 2026. • Announces operational changes that are expected to generate more than $3 million in”
ROCKWELL MEDICAL, INC. reported the twelve months ended December 31, 2025 results: revenue $69.3 million, net income $ (5.3) million, EPS $ (0.15) per share.
“--- Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results • Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively. • Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025. • Generated 21% in gross margin for the fourth quarter 2025,”
ROCKWELL MEDICAL, INC. reported the three months ended December 31, 2025 results: revenue $18.3 million, net income $ (0.6) million, EPS $ (0.01) per share.
“EX-99.1 (EX-99.1) --- Rockwell Medical Announces Fourth Quarter and Full-Year 2025 Financial and Operational Results • Net sales for the fourth quarter and full-year 2025 were $18.3 million and $69.3 million, respectively. • Achieved profitability on an Adjusted EBITDA basis for the second consecutive year in 2025. • Generated 21% in gross margin for the fourth”
ROCKWELL MEDICAL, INC. reported three months ended March 31, 2024 results: revenue $22.7 million, net income Net loss of $1.7 million, EPS $(0.06). Guidance raised.
“by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Rockwell Medical Announces First Quarter 2024 Results, Raises 2024 Guidance • Reports record net sales of $22.7 million for the first quarter of 2024, an increase of 25% over net product sales and a 15% increase over net sales for the same period in 2023. • Reports record gross profit of $3.1”
ROCKWELL MEDICAL, INC. updated its the three months and twelve months ended December 31, 2023 guidance (initiated).
“Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide , today announced financial and operational results for the three months and twelve months ended December 31, 2023.”
ROCKWELL MEDICAL, INC. reported twelve months ended December 31, 2023 results: revenue between $82.8 million and $83.8 million, net income ($9.1) to ($8.1). Guidance reaffirmed.
“in the fourth quarter of 2023. Rockwell Medical is narrowing its full-year 2023 guidance and projects net sales for the twelve months ended December 31, 2023 to be between $82.8 million and $83.8 million, a 14% to 15% increase over net sales of $72.8 million in 2022, and gross profit for the full-year 2023 to be between $7.4 million and $8.4 million, an 80% to”
ROCKWELL MEDICAL, INC. reported three months ended December 31, 2023 results: revenue between $21.3 million and $22.3 million, net income ($2.2) to ($1.2). Guidance reaffirmed.
“8, 2024. 1 Rockwell Medical Preliminary Fourth Quarter and Full-Year 2023 Projected Results Rockwell Medical projects net sales in the fourth quarter of 2023 to be between $21.3 million and $22.3 million, a 10% to 16% increase over net sales of $19.3 million for the same period in 2022; gross profit for the fourth quarter of 2023 to be between $1.6 million and”
ROCKWELL MEDICAL, INC. amended credit facility of $8.0 million with Innovatus Life Sciences Lending Fund I, LP at the greater of (i) Prime Rate and (ii) 7.50%, plus 3.50% maturing fifth anniversary of the Effective Date.
“for the continuation of term loans initially borrowed on or after the Original Effective Date, in an aggregate outstanding principal amount as of the Effective Date of $8.0 million (the “Term Loans”). The Company will make interest-only payments on the Term Loans for thirty months, or up to thirty-six months if certain conditions are met. The Term Loans”
ROCKWELL MEDICAL, INC. reported the three months ended September 30, 2023 results: revenue $23.8 million. Guidance reaffirmed.
“99.1) --- EX-99.1 2 tm2330647d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rockwell Medical Announces Third Quarter 2023 Results · Net sales for the third quarter of 2023 were $23.8 million, including concentrates product sales of $21.6 million, both of which were the highest sales generated to-date for the Company. · Gross profit for the third quarter of 2023”
Joan Lau, PhD was appointed as Class II director at ROCKWELL MEDICAL, INC..
“appointed Joan Lau, PhD to the Board as a Class II director”
ROCKWELL MEDICAL, INC. amended Amended and Restated Products Purchase Agreement with DaVita Inc. (effective 2023-09-18).
“On September 18, 2023, Rockwell Medical, Inc. (the “Company”) and DaVita Inc. (“DaVita”) entered into an Amended and Restated Products Purchase Agreement (the “Amended Agreement”), which amends and restates the Products Purchase Agreement, dated July 1, 2019, as amended, under which the Company supplies DaVita with certain dialysis concentrates.”
Paul McGarry resigned as Senior Vice President, Finance and Chief Accounting Officer at ROCKWELL MEDICAL, INC..
“On September 13, 2023, Paul McGarry notified the Company of his decision to resign as the Company’s Senior Vice President, Finance and Chief Accounting Officer, effective September 29, 2023 (the “Effective Date”), to pursue other opportunities.”
ROCKWELL MEDICAL, INC. updated its the three and six months ended June 30, 2023 guidance (raised).
“On August 14, 2023, Rockwell Medical, Inc. issued a press release and earnings presentation announcing its financial results for the quarter ended June 30, 2023.”
ROCKWELL MEDICAL, INC. reported 2023 results: revenue between $82.0 million and $86.0 million. Guidance raised.
“Rockwell Medical increases its 2023 revenue guidance to between $82.0 million and $86.0 million.”
ROCKWELL MEDICAL, INC. entered into Letter Agreement with Armistice Capital Master Fund Ltd. valued at approximately $13.8 million (effective 2023-07-10).
“On July 10, 2023, the Company entered into a letter agreement (the “Letter Agreement”) with Armistice Capital Master Fund Ltd. (“Armistice”), which held a warrant (the “Prior Warrant”) to purchase 9,900,990 shares of common stock of the Company (the “Common Stock”) with an exercise price of $1.39 per share, offering Armistice the opportunity to exercise the Prior Warrant for cash, provided the Prior Warrant was exercised for cash on or prior to 5:00 P.M. Eastern Time on July 10, 2028 (the “End Date”).”
ROCKWELL MEDICAL, INC. entered into Asset Purchase Agreement with Evoqua Water Technologies LLC valued at $11,000,000 in cash paid at Closing and equal annual installments of $2,500,000 (effective 2023-07-10).
“On July 10, 2023, Rockwell Medical, Inc. (the “Company”) executed and consummated the transactions contemplated by an Asset Purchase Agreement (the “Purchase Agreement”) with Evoqua Water Technologies LLC, a Delaware limited liability company (“Evoqua”).”
ROCKWELL MEDICAL, INC. shareholders approved To approve an amendment and restatement of the Rockwell Medical, Inc. 2018 Long Term Incentive Plan to increase the number of shares reserved for issuance thereunder by 1,600,000 shares. at the 2023-05-23 meeting.
“Proposal Five: To approve an amendment and restatement of the Rockwell Medical, Inc. 2018 Long Term Incentive Plan to increase the number of shares reserved for issuance thereunder by 1,600,000 shares. For Against Abstain Broker Non-Votes 1,994,126 825,079 106,568 4,932,013”
ROCKWELL MEDICAL, INC. shareholders approved To ratify the selection of EisnerAmper LLP as the Company’s independent registered public accounting firm for 2023. at the 2023-05-23 meeting.
“Proposal Four: To ratify the selection of EisnerAmper LLP as the Company’s independent registered public accounting firm for 2023. For Against Abstain 7,696,517 119,313 41,956”
ROCKWELL MEDICAL, INC. shareholders approved To approve, on an advisory basis, the frequency of stockholder advisory votes on compensation of the Company's named executive officers. at the 2023-05-23 meeting.
“Proposal Three: To approve, on an advisory basis, the frequency of stockholder advisory votes on compensation of the Company's named executive officers. 1 Year 2 Years 3 Years Abstain Broker Non-Votes 2,704,562 69,060 95,135 57,016 4,932,013”
ROCKWELL MEDICAL, INC. shareholders approved To approve, on an advisory basis, the compensation of the Company's named executive officers. at the 2023-05-23 meeting.
“Proposal Two: To approve, on an advisory basis, the compensation of the Company's named executive officers. For Against Abstain Broker Non-Votes 2,485,037 337,531 103,205 4,932,013”
ROCKWELL MEDICAL, INC. shareholders approved To elect the two Class II directors to serve for a three-year term expiring at the 2026 annual meeting of stockholders and until his or her successor has been duly elected and qualified. at the 2023-05-23 meeting.
“Proposal One: To elect the two Class II directors to serve for a three-year term expiring at the 2026 annual meeting of stockholders and until his or her successor has been duly elected and qualified. For Against Abstain Broker Non-Votes Mark Ravich 2,015,069 873,941 36,763 4,932,013 Andrea Heslin Smiley 2,639,034 249,295 37,444 4,932,013”
ROCKWELL MEDICAL, INC. reported the three months ended March 31, 2023 results: revenue $19.7 million, net income $1.75 million, EPS $0.10* per share. Guidance reaffirmed.
“in such a filing. --- EX-99.1 (EX-99.1) --- Rockwell Medical Announces First Quarter 2023 Results • Achieved fourth consecutive quarter of revenue growth with new high of $19.7 million, representing a 22.4% increase over the same period in 2022 • Achieved $2.6 million in gross profit, representing a 425% increase over the same period in 2022 • Continued to”
ROCKWELL MEDICAL, INC. engaged Eisner as its auditor.
“On April 7, 2023, the Board appointed Eisner as its new independent registered public accounting firm for the year ended December 31, 2023, effective April 10, 2023”
ROCKWELL MEDICAL, INC. dismissed Marcum, LLP as its auditor.
“on April 7, 2023, the Board, upon recommendation of the Audit Committee of the Board, dismissed Marcum, LLP ("Marcum") as the Company’s independent registered public accounting firm, effective April 10, 2023”
ROCKWELL MEDICAL, INC. engaged EisnerAmper, LLC as its auditor.
“On April 7, 2023, the Company engaged EisnerAmper, LLP ("Eisner") as its new independent registered public accounting firm for the fiscal year ended December 31, 2023”
ROCKWELL MEDICAL, INC. dismissed Marcum, LLP as its auditor.
“on April 7, 2023, the Board dismissed Marcum, LLP ("Marcum") as the Company’s independent registered public accounting firm, effective [immediately]”
ROCKWELL MEDICAL, INC. reported 2023 results: revenue $78.0 Million to $82.0 Million. Guidance initiated.
“Rockwell projects its 2023 guidance as follows: Net Sales $78.0 Million to $82.0 Million Gross Profit $7.0 Million to $9.0 Million”
ROCKWELL MEDICAL, INC. reported the twelve months ended December 31, 2022 results: revenue $72.8 million, net income $18.7 million, EPS $1.89 per share.
“of revenue growth with new high of $19.3 million in the fourth quarter 2022, representing a 26.0% increase over same period in 2021 • Exceeded annual revenue guidance generating $72.8 million in 2022, representing a 17.6% increase year-over-year and the highest full-year revenue to date for the Company • Reduced debt to $10.0 million at December 31, 2022, representing”
ROCKWELL MEDICAL, INC. reported the three months ended December 31, 2022 results: revenue $19.3 million, net income $2.4 million, EPS $0.20 per share.
“--- Rockwell Medical Announces Fourth Quarter and Full-Year 2022 Financial and Operational Results • Achieved third consecutive quarter of revenue growth with new high of $19.3 million in the fourth quarter 2022, representing a 26.0% increase over same period in 2021 • Exceeded annual revenue guidance generating $72.8 million in 2022, representing a 17.6%”
ROCKWELL MEDICAL, INC. reported third quarter ended September 30, 2022 results: revenue $18.7 million.
“Revenue for the three months ended September 30, 2022 was $18.7 million”
Mark Strobeck was appointed as President and Chief Executive Officer at ROCKWELL MEDICAL, INC..
“the Board appointed Mark Strobeck, Ph.D. as the Company’s President and Chief Executive Officer and as a Class III Director to serve until the Company’s 2024 Annual Meeting of Stockholders and until his successor is duly elected and qualified, effective July 1, 2022”
Russell H. Ellison departed as President and Chief Executive Officer at ROCKWELL MEDICAL, INC..
“Russell H. Ellison, M.D., M.Sc., will be stepping down from his role as the President and Chief Executive Officer of the Company, effective as of June 30, 2022”
ROCKWELL MEDICAL, INC. reported three months ended March 31, 2022 results: revenue $16.1 million.
“Revenues were $16.1 million for the three months ended March 31, 2022, compared to $15.5 million for the three months ended March 31, 2021.”
John P. McLaughlin resigned as Chairman of the Board at ROCKWELL MEDICAL, INC..
“On March 20, 2022, John P. McLaughlin notified the board of directors (the “Board”) of Rockwell Medical, Inc. (the “Company”) of his intent to resign as a member of the Board and as Chairman of the Board effective as of April 1, 2022.”
Raymond Pratt resigned as Chief Development Officer at ROCKWELL MEDICAL, INC..
“On March 14, 2022, Raymond Pratt notified the Company of his decision to resign as the Company’s Chief Development Officer, effective as of March 25, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.